An Extension Study to WA19977 in Patients With Active Polyarticular-Course Juvenile Idiopathic Arthritis
Study Details
Study Description
Brief Summary
This long-term, interventional, open-label extension study will evaluate the safety and efficacy of RoActemra/Actemra (tocilizumab) in patients from Poland and Russia with polyarticular-course juvenile idiopathic arthritis who completed the WA19977 study. Patients will receive RoActemra/Actemra 8 mg/kg every 4 weeks. The anticipated time on study treatment is 104 weeks.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: 1
|
Drug: RoActemra/Actemra (tocilizumab)
Tocilizumab 8 mg/kg every 4 weeks for 104 weeks
|
Outcome Measures
Primary Outcome Measures
- Percentage of Participants With Adverse Events (AEs) [Baseline to 12 weeks after last actual study medication (up to 101 weeks)]
AE: unfavorable and unintended sign, symptom, or disease associated with use of treatment, regardless of treatment relation. Pre-existing conditions that worsened and laboratory or clinical tests that resulted in change in treatment or discontinuation from treatment were reported as AEs. Serious AE: resulted in death, life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was congenital anomaly/birth defect or was medically significant. Severe AE: AE that caused inability to work or perform normal daily activity. AEs of special interest: Serious infections (including opportunistic infections), Myocardial infarction/Acute coronary syndrome, Gastrointestinal perforations and related AE, Malignant neoplasms, Anaphylaxis event, Demyelination-related events, Stroke, Spontaneous or serious bleeding, Serious/medically significant hepatic events. Any AE included serious and non-serious AE.
Secondary Outcome Measures
- Percentage of Participants With JIA ACR 30 Response at Weeks 12, 24 and End of Follow Up [Baseline, Week 12, 24, End of Follow up (up to 101 weeks)]
JIA ACR30 response was defined as 3 of any 6 core outcome variables improved by at least 30% of the baseline assessments, with no more than 1 of the remaining variables worsened by more than 30%. Six core variables were: Physician global assessment (PGA) of disease activity using Visual Analog Scale (VAS) from left end of line 0 (inactive arthritis) to right end of line 100 (very active arthritis); Patient/parent global assessment (PtGA) of overall well-being using a VAS from left end of line 0 (very well) to right end of line 100 (very poor); Number of joints with active arthritis (joints with swelling not due to deformity or joints with limitation of motion and with pain, tenderness or both); Number of joints with limitation of movement; Health Assessment Questionnaire: 20 questions in 8 areas (dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities) answered on a scale of 0=without difficulty to 3=unable to do; and Erythrocyte Sedimentation Rate (ESR).
- Percentage of Participants With JIA ACR 50 Response at Weeks 12, 24 and End of Follow up [Baseline, Week 12, 24, End of Follow up (up to 101 weeks)]
JIA ACR50 response was defined as 3 of any 6 core outcome variables improved by at least 50% of the baseline assessments, with no more than 1 of the remaining variables worsened by more than 30%. Six core variables were: PGA of disease activity using VAS from left end of line 0 (inactive arthritis) to right end of line 100 (very active arthritis); PtGA of overall well-being using a VAS from left end of line 0 (very well) to right end of line 100 (very poor); Number of joints with active arthritis (joints with swelling not due to deformity or joints with limitation of motion and with pain, tenderness or both); Number of joints with limitation of movement; Health Assessment Questionnaire: 20 questions in 8 areas (dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities) answered on a scale of 0=without difficulty to 3=unable to do; and ESR.
- Percentage of Participants With JIA ACR 70 Response at Weeks 12, 24 and End of Follow up [Baseline, Week 12, 24, End of Follow up (up to 101 weeks)]
JIA ACR70 response was defined as 3 of any 6 core outcome variables improved by at least 70% of the baseline assessments, with no more than 1 of the remaining variables worsened by more than 30%. Six core variables were: PGA of disease activity using VAS from left end of line 0 (inactive arthritis) to right end of line 100 (very active arthritis); PtGA of overall well-being using a VAS from left end of line 0 (very well) to right end of line 100 (very poor); Number of joints with active arthritis (joints with swelling not due to deformity or joints with limitation of motion and with pain, tenderness or both); Number of joints with limitation of movement; Health Assessment Questionnaire: 20 questions in 8 areas (dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities) answered on a scale of 0=without difficulty to 3=unable to do; and ESR
- Percentage of Participants With JIA ACR 90 Response at Weeks 12, 24 and End of Follow up [Baseline, Week 12, 24, End of Follow up (up to 101 weeks)]
JIA ACR90 response was defined as 3 of any 6 core outcome variables improved by at least 90% of the baseline assessments, with no more than 1 of the remaining variables worsened by more than 30%. Six core variables were: PGA of disease activity using VAS from left end of line 0 (inactive arthritis) to right end of line 100 (very active arthritis); PtGA of overall well-being using a VAS from left end of line 0 (very well) to right end of line 100 (very poor); Number of joints with active arthritis (joints with swelling not due to deformity or joints with limitation of motion and with pain, tenderness or both); Number of joints with limitation of movement; Health Assessment Questionnaire: 20 questions in 8 areas (dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities) answered on a scale of 0=without difficulty to 3=unable to do; and ESR.
- Percentage of Participants With Inactive Disease at Week 12, 24 and End of Follow up [Baseline, Week 12, 24, End of Follow up (up to 101 weeks)]
Criteria for Inactive Disease: 1) No joints with active arthritis (joints with swelling not due to deformity or joints with limitation of motion and with pain, tenderness or both), 2) No fever, rash, serositis, splenomegaly, hepatomegaly (by physical exam) or generalized lymphadenopathy attributable to systemic juvenile idiopathic arthritis (sJIA), 3) Normal ESR (less than [<] 20 millimeters per hour [mm/hour]), and 4) PGA of disease activity using VAS indicated no disease activity (where no disease activity is considered to be a score less than or equal to [≤]10 mm on a 100 mm VAS where left end of line 0 [inactive arthritis] to right end of line 100 [very active arthritis]).
- Percentage of Participants With Clinical Remission at Week 12, 24 and End of Follow up [Baseline, Week 12, 24, End of Follow up (up to 101 weeks)]
Clinical remission: inactive disease for minimum of 6 continuous months while on medication (Level 1); off oral corticosteroid medications but still on tocilizumab (Level 2); off both methotrexate and oral corticosteroids but still on tocilizumab (Level 3); or off all anti-arthritis medications-oral corticosteroids, methotrexate, non-steroidal anti-inflammatory drugs but still on tocilizumab (Level 4). Inactive disease: No joints with active arthritis (joints with swelling not due to deformity or joints with limitation of motion and with pain, tenderness or both); No fever, rash, serositis, splenomegaly, hepatomegaly (by physical exam) or generalized lymphadenopathy attributable to sJIA; Normal ESR (<20 mm/hour); PGA of disease activity indicated no disease activity (score ≤10 mm on a 100 mm VAS where 0 [inactive arthritis] and 100 [very active arthritis]). Overall percentage of participants with clinical remission (any level) are reported.
- Change From Baseline in Joints With Active Arthritis at Weeks 12, 24, 36, 48, 60, 72, 84, End of Follow up [Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks)]
Joint with active arthritis was defined as a joint with swelling not due to deformity or joints with limitation of motion and with pain, tenderness or both.
- Change From Baseline in Number of Joints With Limitation of Movement at Weeks 12, 24, 36, 48, 60, 72, 84, End of Follow up [Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks)]
The maximum number of joints with limitation of movement is 67 and these were defined as those with 'limitation of motion'.
- Change From Baseline in PGA of Disease Activity at Weeks 12, 24, 36, 48, 60, 72, 84, End of Follow up [Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks)]
The physician provides a rating of the participant's arthritis disease activity on a 0 to 100 mm horizontal scale. The extreme left end of the line represents 'arthritis inactive' (ie, symptom-free and no arthritis symptoms) and the extreme right end represents 'arthritis very active'. A higher score indicates more disease activity. A negative change score indicates improvement.
- Change From Baseline in PtGA of Overall Well-Being at Weeks 12, 24, 36, 48, 60, 72, 84, End of Follow up [Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks)]
The participant or parent/guardian, as appropriate, provides a rating of the participant's well-being on a 0 to 100 mm horizontal scale. The extreme left end of the line represents 'very well' (ie, symptom-free and no arthritis disease activity) and the extreme right end represents 'very poor' (ie, maximum arthritis disease activity). A higher score indicates poorer well-being. A negative change score indicates improvement.
- Change From Baseline in ESR at Weeks 12, 24, 36, 48, 60, 72, 84, End of Follow up [Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks)]
- Change From Baseline in Childhood Health Assessment - Disability Index (CHAQ-DI) at Weeks 12, 24, 36, 48, 60, 72, 84, End of Follow up [Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks)]
The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. There are 4 possible responses to each question (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do). A domain score is the highest score in that domain. To calculate the overall score, the participant must have a domain score in at least 6 of the 8 domains. The CHAQ-DI score is the sum of the domain scores divided by the number of domains that have a non-missing score and ranges from 0 (best) to 3 (worst). A higher score indicates less ability.
- Percentage of Participants With Minimally Important Improvement in the CHAQ-DI Score at Weeks 12, 24, 36, 48, 60, 72, 84 and End of Follow up [Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks)]
The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. There are 4 possible responses to each question (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do). A domain score is the highest score in that domain. To calculate the overall score, the participant must have a domain score in at least 6 of the 8 domains. The CHAQ-DI score is the sum of the domain scores divided by the number of domains that have a non-missing score and ranges from 0 (best) to 3 (worst). A higher score indicates less ability. A minimally important improvement was defined as at least a 0.13 improvement in CHAQ-DI score from baseline.
- Change From Baseline in CHAQ-DI (Activitiy) Score at Weeks 12, 24, 36, 48, 60, 72, 84 and End of Follow up [Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks)]
The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Activity component was measured on 0-3 scale (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do).
- Change From Baseline in CHAQ-DI (Arising) Score at Weeks 12, 24, 36, 48, 60, 72, 84 and End of Follow up [Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks)]
The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Arising component was measured on 0-3 scale (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do).
- Change From Baseline in CHAQ-DI (Dressing and Grooming) Score at Weeks 12, 24, 36, 48, 60, 72, 84 and End of Follow up [Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks)]
The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Dressing and Grooming component was measured on 0-3 scale (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do).
- Change From Baseline in CHAQ-DI (Eating) Score at Weeks 12, 24, 36, 48, 60, 72, 84 and End of Follow up [Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks)]
The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Eating component was measured on 0-3 scale (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do).
- Change From Baseline in CHAQ-DI (Grip) Score at Weeks 12, 24, 36, 48, 60, 72, 84 and End of Follow up [Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks)]
The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Grip component was measured on 0-3 scale (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do).
- Change From Baseline in CHAQ-DI (Hygiene) Score at Weeks 12, 24, 36, 48, 60, 72, 84 and End of Follow up [Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks)]
The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Hygiene component was measured on 0-3 scale (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do).
- Change From Baseline in CHAQ-DI (Reach) Score at Weeks 12, 24, 36, 48, 60, 72, 84 and End of Follow up [Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks)]
The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Reach component was measured on 0-3 scale (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do).
- Change From Baseline in CHAQ-DI (Walking) Score at Weeks 12, 24, 36, 48, 60, 72, 84 and End of Follow up [Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks)]
The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Walking component was measured on 0-3 scale (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do).
- Absolute C-Reactive Protein Levels [Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, End of follow up (up to 101 weeks)]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients who completed 104 weeks of study WA19977 with at least a JIA ACR30 clinical response to RoActemra/Actemra and no serious adverse event or adverse event
-
Written informed consent obtained from patient if patient is 18 years of age and older, or if under the age of 18 years from parents or legal guardian
Exclusion Criteria:
-
Patient did not benefit from RoActemra/Actemra therapy in study WA19977
-
Treatment with any investigational drug since the last administration of study drug in the core study WA19977
-
Patients developed any other autoimmune rheumatic disease other than the permitted JIA subsets
-
Any significant medical or surgical condition that would jeopardize patient's safety
-
Current serious uncontrolled concomitant disease or infection
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Wojewodzki Szpital Dzieciecy Im. J. Brudzinskiego | Bydgoszcz | Poland | 85-667 | |
| 2 | Wojewodzki Specjalistyczny Szpital Dzieciecy Sw Ludwika; Oddzial Dzieci Starszych | Kraków | Poland | 31-503 | |
| 3 | Uniwersytecki Szpital Kliniczny Nr 4 im. M. Konopnickiej; Oddz. Kardiolog. i Reumatolog. dla Dzieci | Lodz | Poland | 91-738 | |
| 4 | Dzieciecy Szpital Kliniczny IM. Prof. A. Gebali; Oddzial Pediatrii Chorob Pluc I Reumatologii | Lublin | Poland | 20-093 | |
| 5 | Centrum Pediatrii im Jana Pawla II; Oddzial Reumatologiczny | Sosnowiec | Poland | 41-218 | |
| 6 | Scientific Research Institute | Moscow | Russian Federation | 115522 | |
| 7 | SBEI of HPI The 1st Moscow State Medical University n.a. I.M. Sechenov of MOH of RF | Moscow | Russian Federation | 119021 | |
| 8 | SI Sceintific children health center RAMS | Moscow | Russian Federation | 119991 | |
| 9 | GOU VPO Rostovskiy state medical university Roszdrav | Rostov-na-donu | Russian Federation | 344022 | |
| 10 | Saint-Petersburg State; Pediatrics Medical Academy | Saint-Petersburg | Russian Federation | 194100 | |
| 11 | Samara Regional Clinical Cardiology Dispensary | Samara | Russian Federation | 443070 |
Sponsors and Collaborators
- Hoffmann-La Roche
Investigators
- Study Director: Clinical Trials, Hoffmann-La Roche
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ML27783
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail | Participants who completed Visit 33 (Week 104) of the core study WA19977 (NCT00988221) with at least juvenile idiopathic arthritis (JIA) American College of Rheumatology (ACR) 30 clinical response were eligible to continue the study therapy within this long-term extension study in Russia and Poland. |
| Arm/Group Title | Tocilizumab |
|---|---|
| Arm/Group Description | Participants received tocilizumab 8 milligrams per kilograms (mg/kg) via intravenous (IV) infusion, once every 4 weeks for up to 104 weeks or until tocilizumab became commercially available, whichever occurred first. |
| Period Title: Overall Study | |
| STARTED | 41 |
| COMPLETED | 0 |
| NOT COMPLETED | 41 |
Baseline Characteristics
| Arm/Group Title | Tocilizumab |
|---|---|
| Arm/Group Description | Participants received tocilizumab 8 mg/kg via IV infusion, once every 4 weeks for up to 104 weeks or until tocilizumab became commercially available, whichever occurred first. |
| Overall Participants | 41 |
| Age (years) [Mean (Standard Deviation) ] | |
| Mean (Standard Deviation) [years] |
12.0
(4.45)
|
| Sex: Female, Male (Count of Participants) | |
| Female |
33
80.5%
|
| Male |
8
19.5%
|
Outcome Measures
| Title | Percentage of Participants With Adverse Events (AEs) |
|---|---|
| Description | AE: unfavorable and unintended sign, symptom, or disease associated with use of treatment, regardless of treatment relation. Pre-existing conditions that worsened and laboratory or clinical tests that resulted in change in treatment or discontinuation from treatment were reported as AEs. Serious AE: resulted in death, life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was congenital anomaly/birth defect or was medically significant. Severe AE: AE that caused inability to work or perform normal daily activity. AEs of special interest: Serious infections (including opportunistic infections), Myocardial infarction/Acute coronary syndrome, Gastrointestinal perforations and related AE, Malignant neoplasms, Anaphylaxis event, Demyelination-related events, Stroke, Spontaneous or serious bleeding, Serious/medically significant hepatic events. Any AE included serious and non-serious AE. |
| Time Frame | Baseline to 12 weeks after last actual study medication (up to 101 weeks) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety population |
| Arm/Group Title | Tocilizumab |
|---|---|
| Arm/Group Description | Participants received tocilizumab 8 mg/kg via IV infusion,once every 4 weeks for up to 104 weeks or until tocilizumab became commercially available, whichever occurred first. |
| Measure Participants | 41 |
| Any AEs |
56.1
136.8%
|
| Any Treatment Related AEs |
29.3
71.5%
|
| Any SAEs |
7.3
17.8%
|
| Any Severe AEs |
2.4
5.9%
|
| Any Life Threatening AEs |
0.0
0%
|
| AEs of Special Interest |
0.0
0%
|
| AE Leading to Dosage Modification/Interruption |
22.0
53.7%
|
| Withdrawal Due to AEs |
2.4
5.9%
|
| Withdrawal Due to SAEs |
2.4
5.9%
|
| Withdrawal Due to AEs of Special Interest |
0.0
0%
|
| Title | Percentage of Participants With JIA ACR 30 Response at Weeks 12, 24 and End of Follow Up |
|---|---|
| Description | JIA ACR30 response was defined as 3 of any 6 core outcome variables improved by at least 30% of the baseline assessments, with no more than 1 of the remaining variables worsened by more than 30%. Six core variables were: Physician global assessment (PGA) of disease activity using Visual Analog Scale (VAS) from left end of line 0 (inactive arthritis) to right end of line 100 (very active arthritis); Patient/parent global assessment (PtGA) of overall well-being using a VAS from left end of line 0 (very well) to right end of line 100 (very poor); Number of joints with active arthritis (joints with swelling not due to deformity or joints with limitation of motion and with pain, tenderness or both); Number of joints with limitation of movement; Health Assessment Questionnaire: 20 questions in 8 areas (dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities) answered on a scale of 0=without difficulty to 3=unable to do; and Erythrocyte Sedimentation Rate (ESR). |
| Time Frame | Baseline, Week 12, 24, End of Follow up (up to 101 weeks) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety population |
| Arm/Group Title | Tocilizumab |
|---|---|
| Arm/Group Description | Participants received tocilizumab 8 mg/kg via IV infusion, once every 4 weeks for up to 104 weeks or until tocilizumab became commercially available whichever, occurred first. |
| Measure Participants | 41 |
| Baseline |
100.0
243.9%
|
| Week 12 |
100.0
243.9%
|
| Week 24 |
100.0
243.9%
|
| Follow up |
80.5
196.3%
|
| Title | Percentage of Participants With JIA ACR 50 Response at Weeks 12, 24 and End of Follow up |
|---|---|
| Description | JIA ACR50 response was defined as 3 of any 6 core outcome variables improved by at least 50% of the baseline assessments, with no more than 1 of the remaining variables worsened by more than 30%. Six core variables were: PGA of disease activity using VAS from left end of line 0 (inactive arthritis) to right end of line 100 (very active arthritis); PtGA of overall well-being using a VAS from left end of line 0 (very well) to right end of line 100 (very poor); Number of joints with active arthritis (joints with swelling not due to deformity or joints with limitation of motion and with pain, tenderness or both); Number of joints with limitation of movement; Health Assessment Questionnaire: 20 questions in 8 areas (dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities) answered on a scale of 0=without difficulty to 3=unable to do; and ESR. |
| Time Frame | Baseline, Week 12, 24, End of Follow up (up to 101 weeks) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety population |
| Arm/Group Title | Tocilizumab |
|---|---|
| Arm/Group Description | Participants received tocilizumab 8 mg/kg via IV infusion, once every 4 weeks for up to 104 weeks or until tocilizumab became commercially available whichever, occurred first. |
| Measure Participants | 41 |
| Baseline |
100.0
243.9%
|
| Week 12 |
100.0
243.9%
|
| Week 24 |
100.0
243.9%
|
| Follow up |
80.5
196.3%
|
| Title | Percentage of Participants With JIA ACR 70 Response at Weeks 12, 24 and End of Follow up |
|---|---|
| Description | JIA ACR70 response was defined as 3 of any 6 core outcome variables improved by at least 70% of the baseline assessments, with no more than 1 of the remaining variables worsened by more than 30%. Six core variables were: PGA of disease activity using VAS from left end of line 0 (inactive arthritis) to right end of line 100 (very active arthritis); PtGA of overall well-being using a VAS from left end of line 0 (very well) to right end of line 100 (very poor); Number of joints with active arthritis (joints with swelling not due to deformity or joints with limitation of motion and with pain, tenderness or both); Number of joints with limitation of movement; Health Assessment Questionnaire: 20 questions in 8 areas (dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities) answered on a scale of 0=without difficulty to 3=unable to do; and ESR |
| Time Frame | Baseline, Week 12, 24, End of Follow up (up to 101 weeks) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety population |
| Arm/Group Title | Tocilizumab |
|---|---|
| Arm/Group Description | Participants received tocilizumab 8 mg/kg via IV infusion, once every 4 weeks for up to 104 weeks or until tocilizumab became commercially available, whichever occurred first. |
| Measure Participants | 41 |
| Baseline |
100.0
243.9%
|
| Week 12 |
100.0
243.9%
|
| Week 24 |
97.6
238%
|
| Follow up |
78.0
190.2%
|
| Title | Percentage of Participants With JIA ACR 90 Response at Weeks 12, 24 and End of Follow up |
|---|---|
| Description | JIA ACR90 response was defined as 3 of any 6 core outcome variables improved by at least 90% of the baseline assessments, with no more than 1 of the remaining variables worsened by more than 30%. Six core variables were: PGA of disease activity using VAS from left end of line 0 (inactive arthritis) to right end of line 100 (very active arthritis); PtGA of overall well-being using a VAS from left end of line 0 (very well) to right end of line 100 (very poor); Number of joints with active arthritis (joints with swelling not due to deformity or joints with limitation of motion and with pain, tenderness or both); Number of joints with limitation of movement; Health Assessment Questionnaire: 20 questions in 8 areas (dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities) answered on a scale of 0=without difficulty to 3=unable to do; and ESR. |
| Time Frame | Baseline, Week 12, 24, End of Follow up (up to 101 weeks) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety population |
| Arm/Group Title | Tocilizumab |
|---|---|
| Arm/Group Description | Participants received tocilizumab 8 mg/kg via IV infusion, once every 4 weeks for up to 104 weeks or until tocilizumab became commercially available, whichever occurred first. |
| Measure Participants | 41 |
| Baseline |
73.2
178.5%
|
| Week 12 |
78.0
190.2%
|
| Week 24 |
80.5
196.3%
|
| Follow up |
75.6
184.4%
|
| Title | Percentage of Participants With Inactive Disease at Week 12, 24 and End of Follow up |
|---|---|
| Description | Criteria for Inactive Disease: 1) No joints with active arthritis (joints with swelling not due to deformity or joints with limitation of motion and with pain, tenderness or both), 2) No fever, rash, serositis, splenomegaly, hepatomegaly (by physical exam) or generalized lymphadenopathy attributable to systemic juvenile idiopathic arthritis (sJIA), 3) Normal ESR (less than [<] 20 millimeters per hour [mm/hour]), and 4) PGA of disease activity using VAS indicated no disease activity (where no disease activity is considered to be a score less than or equal to [≤]10 mm on a 100 mm VAS where left end of line 0 [inactive arthritis] to right end of line 100 [very active arthritis]). |
| Time Frame | Baseline, Week 12, 24, End of Follow up (up to 101 weeks) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety population |
| Arm/Group Title | Tocilizumab |
|---|---|
| Arm/Group Description | Participants received tocilizumab 8 mg/kg via IV infusion, once every 4 weeks for up to 104 weeks or until tocilizumab became commercially available, whichever occurred first. |
| Measure Participants | 41 |
| Baseline |
63.4
154.6%
|
| Week 12 |
65.9
160.7%
|
| Week 24 |
75.6
184.4%
|
| Follow up |
61.0
148.8%
|
| Title | Percentage of Participants With Clinical Remission at Week 12, 24 and End of Follow up |
|---|---|
| Description | Clinical remission: inactive disease for minimum of 6 continuous months while on medication (Level 1); off oral corticosteroid medications but still on tocilizumab (Level 2); off both methotrexate and oral corticosteroids but still on tocilizumab (Level 3); or off all anti-arthritis medications-oral corticosteroids, methotrexate, non-steroidal anti-inflammatory drugs but still on tocilizumab (Level 4). Inactive disease: No joints with active arthritis (joints with swelling not due to deformity or joints with limitation of motion and with pain, tenderness or both); No fever, rash, serositis, splenomegaly, hepatomegaly (by physical exam) or generalized lymphadenopathy attributable to sJIA; Normal ESR (<20 mm/hour); PGA of disease activity indicated no disease activity (score ≤10 mm on a 100 mm VAS where 0 [inactive arthritis] and 100 [very active arthritis]). Overall percentage of participants with clinical remission (any level) are reported. |
| Time Frame | Baseline, Week 12, 24, End of Follow up (up to 101 weeks) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety population |
| Arm/Group Title | Tocilizumab |
|---|---|
| Arm/Group Description | Participants received tocilizumab 8 mg/kg via IV infusion, once every 4 weeks for up to 104 weeks or until tocilizumab became commercially available, whichever occurred first. |
| Measure Participants | 41 |
| Baseline |
43.9
107.1%
|
| Week 12 |
46.3
112.9%
|
| Week 24 |
48.8
119%
|
| Follow up |
46.3
112.9%
|
| Title | Change From Baseline in Joints With Active Arthritis at Weeks 12, 24, 36, 48, 60, 72, 84, End of Follow up |
|---|---|
| Description | Joint with active arthritis was defined as a joint with swelling not due to deformity or joints with limitation of motion and with pain, tenderness or both. |
| Time Frame | Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety population. Here, 'n' signifies the number of participants with available data for specified category. |
| Arm/Group Title | Tocilizumab |
|---|---|
| Arm/Group Description | Participants received tocilizumab 8 mg/kg via IV infusion, once every 4 weeks for up to 104 weeks or until tocilizumab became commercially available, whichever occurred first. |
| Measure Participants | 41 |
| Baseline (n=41) |
1.4
(2.68)
|
| Change From Baseline at Week 12 (n=41) |
-0.1
(1.70)
|
| Change From Baseline at Week 24 (n=41) |
-0.4
(4.56)
|
| Change From Baseline at Week 36 (n=35) |
-1.4
(2.80)
|
| Change From Baseline at Week 48 (n=22) |
-1.7
(3.34)
|
| Change From Baseline at Week 60 (n=17) |
0.4
(8.17)
|
| Change From Baseline at Week 72 (n=10) |
1.9
(7.52)
|
| Change From Baseline at Week 84 (n=7) |
3.9
(11.55)
|
| Change From Baseline at Follow Up (n=33) |
1.2
(4.14)
|
| Title | Change From Baseline in Number of Joints With Limitation of Movement at Weeks 12, 24, 36, 48, 60, 72, 84, End of Follow up |
|---|---|
| Description | The maximum number of joints with limitation of movement is 67 and these were defined as those with 'limitation of motion'. |
| Time Frame | Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety population. Here, 'n' signifies the number of participants with available data for specified category. |
| Arm/Group Title | Tocilizumab |
|---|---|
| Arm/Group Description | Participants received tocilizumab 8 mg/kg via IV infusion, once every 4 weeks for up to 104 weeks or until tocilizumab became commercially available, whichever occurred first. |
| Measure Participants | 41 |
| Baseline (n=41) |
3.5
(6.30)
|
| Change From Baseline at Week 12 (n=41) |
-0.6
(2.23)
|
| Change From Baseline at Week 24 (n=41) |
-0.9
(2.75)
|
| Change From Baseline at Week 36 (n=35) |
-1.3
(3.14)
|
| Change From Baseline at Week 48 (n=22) |
-1.5
(4.21)
|
| Change From Baseline at Week 60 (n=17) |
-1.2
(5.10)
|
| Change From Baseline at Week 72 (n=10) |
0.0
(1.83)
|
| Change From Baseline at Week 84 (n=7) |
0.7
(3.09)
|
| Change From Baseline at Follow Up (n=33) |
2.6
(5.80)
|
| Title | Change From Baseline in PGA of Disease Activity at Weeks 12, 24, 36, 48, 60, 72, 84, End of Follow up |
|---|---|
| Description | The physician provides a rating of the participant's arthritis disease activity on a 0 to 100 mm horizontal scale. The extreme left end of the line represents 'arthritis inactive' (ie, symptom-free and no arthritis symptoms) and the extreme right end represents 'arthritis very active'. A higher score indicates more disease activity. A negative change score indicates improvement. |
| Time Frame | Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety population. Here, 'n' signifies the number of participants with available data for specified category. |
| Arm/Group Title | Tocilizumab |
|---|---|
| Arm/Group Description | Participants received tocilizumab 8 mg/kg via IV infusion, once every 4 weeks for up to 104 weeks or until tocilizumab became commercially available, whichever occurred first. |
| Measure Participants | 41 |
| Baseline (n=41) |
4.5
(4.99)
|
| Change From Baseline at Week 12 (n=41) |
1.0
(5.66)
|
| Change From Baseline at Week 24 (n=41) |
0.1
(4.97)
|
| Change From Baseline at Week 36 (n=35) |
-0.6
(4.29)
|
| Change From Baseline at Week 48 (n=22) |
-0.4
(5.80)
|
| Change From Baseline at Week 60 (n=17) |
0.4
(6.52)
|
| Change From Baseline at Week 72 (n=10) |
1.0
(6.50)
|
| Change From Baseline at Week 84 (n=7) |
2.9
(13.09)
|
| Change From Baseline at Follow Up (n=33) |
4.4
(8.65)
|
| Title | Change From Baseline in PtGA of Overall Well-Being at Weeks 12, 24, 36, 48, 60, 72, 84, End of Follow up |
|---|---|
| Description | The participant or parent/guardian, as appropriate, provides a rating of the participant's well-being on a 0 to 100 mm horizontal scale. The extreme left end of the line represents 'very well' (ie, symptom-free and no arthritis disease activity) and the extreme right end represents 'very poor' (ie, maximum arthritis disease activity). A higher score indicates poorer well-being. A negative change score indicates improvement. |
| Time Frame | Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety population. Here, 'n' signifies the number of participants with available data for specified category. |
| Arm/Group Title | Tocilizumab |
|---|---|
| Arm/Group Description | Participants received tocilizumab 8 mg/kg via IV infusion, once every 4 weeks for up to 104 weeks or until tocilizumab became commercially available, whichever occurred first. |
| Measure Participants | 41 |
| Baseline (n=41) |
4.0
(5.72)
|
| Change From Baseline at Week 12 (n=41) |
-0.2
(3.31)
|
| Change From Baseline at Week 24 (n=41) |
-1.5
(4.38)
|
| Change From Baseline at Week 36 (n=35) |
-2.2
(4.34)
|
| Change From Baseline at Week 48 (n=22) |
-2.2
(4.89)
|
| Change From Baseline at Week 60 (n=17) |
-1.2
(2.08)
|
| Change From Baseline at Week 72 (n=10) |
-0.9
(1.60)
|
| Change From Baseline at Week 84 (n=7) |
-0.9
(2.19)
|
| Change From Baseline at Follow Up (n=33) |
3.2
(7.39)
|
| Title | Change From Baseline in ESR at Weeks 12, 24, 36, 48, 60, 72, 84, End of Follow up |
|---|---|
| Description | |
| Time Frame | Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety population. Here, 'n' signifies the number of participants with available data for specified category. |
| Arm/Group Title | Tocilizumab |
|---|---|
| Arm/Group Description | Participants received tocilizumab 8 mg/kg via IV infusion, once every 4 weeks for up to 104 weeks or until tocilizumab became commercially available, whichever occurred first. |
| Measure Participants | 41 |
| Baseline (n=41) |
5.0
(4.08)
|
| Change From Baseline at Week 12 (n=41) |
-0.95
(3.83)
|
| Change From Baseline at Week 24 (n=41) |
-0.9
(5.01)
|
| Change From Baseline at Week 36 (n=35) |
-1.2
(5.26)
|
| Change From Baseline at Week 48 (n=22) |
-0.9
(3.30)
|
| Change From Baseline at Week 60 (n=17) |
-0.35
(5.22)
|
| Change From Baseline at Week 72 (n=10) |
0.5
(6.88)
|
| Change From Baseline at Week 84 (n=7) |
3.3
(14.68)
|
| Change From Baseline at Follow Up (n=33) |
5.9
(8.07)
|
| Title | Change From Baseline in Childhood Health Assessment - Disability Index (CHAQ-DI) at Weeks 12, 24, 36, 48, 60, 72, 84, End of Follow up |
|---|---|
| Description | The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. There are 4 possible responses to each question (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do). A domain score is the highest score in that domain. To calculate the overall score, the participant must have a domain score in at least 6 of the 8 domains. The CHAQ-DI score is the sum of the domain scores divided by the number of domains that have a non-missing score and ranges from 0 (best) to 3 (worst). A higher score indicates less ability. |
| Time Frame | Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety population. Here, 'n' signifies the number of participants with available data for specified category. |
| Arm/Group Title | Tocilizumab |
|---|---|
| Arm/Group Description | Participants received tocilizumab 8 mg/kg via IV infusion, once every 4 weeks for up to 104 weeks or until tocilizumab became commercially available, whichever occurred first. |
| Measure Participants | 41 |
| Baseline (n=41) |
0.1
(0.24)
|
| Change From Baseline at Week 12 (n=41) |
-0.0
(0.06)
|
| Change From Baseline at Week 24 (n=41) |
0.0
(0.09)
|
| Change From Baseline at Week 36 (n=35) |
-0.0
(0.09)
|
| Change From Baseline at Week 48 (n=22) |
-0.1
(0.15)
|
| Change From Baseline at Week 60 (n=17) |
0.0
(0.08)
|
| Change From Baseline at Week 72 (n=10) |
-0.1
(0.09)
|
| Change From Baseline at Week 84 (n=7) |
-0.1
(0.26)
|
| Change From Baseline at Follow Up (n=33) |
0.1
(0.25)
|
| Title | Percentage of Participants With Minimally Important Improvement in the CHAQ-DI Score at Weeks 12, 24, 36, 48, 60, 72, 84 and End of Follow up |
|---|---|
| Description | The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. There are 4 possible responses to each question (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do). A domain score is the highest score in that domain. To calculate the overall score, the participant must have a domain score in at least 6 of the 8 domains. The CHAQ-DI score is the sum of the domain scores divided by the number of domains that have a non-missing score and ranges from 0 (best) to 3 (worst). A higher score indicates less ability. A minimally important improvement was defined as at least a 0.13 improvement in CHAQ-DI score from baseline. |
| Time Frame | Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety population |
| Arm/Group Title | Tocilizumab |
|---|---|
| Arm/Group Description | Participants received tocilizumab 8 mg/kg via IV infusion, once every 4 weeks for up to 104 weeks or until tocilizumab became commercially available, whichever occurred first. |
| Measure Participants | 41 |
| Week 12 |
2.4
5.9%
|
| Week 24 |
2.4
5.9%
|
| Week 36 |
5.7
13.9%
|
| Week 48 |
18.2
44.4%
|
| Week 72 |
10.0
24.4%
|
| Week 84 |
28.6
69.8%
|
| Follow Up |
15.2
37.1%
|
| Title | Change From Baseline in CHAQ-DI (Activitiy) Score at Weeks 12, 24, 36, 48, 60, 72, 84 and End of Follow up |
|---|---|
| Description | The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Activity component was measured on 0-3 scale (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do). |
| Time Frame | Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety population. Here, 'n' signifies the number of participants with available data for specified category. |
| Arm/Group Title | Tocilizumab |
|---|---|
| Arm/Group Description | Participants received tocilizumab 8 mg/kg via IV infusion, once every 4 weeks for up to 104 weeks or until tocilizumab became commercially available, whichever occurred first. |
| Measure Participants | 41 |
| Baseline (n=40) |
0.2
(0.41)
|
| Change From Baseline at Week 12 (n=39) |
0.0
(0.16)
|
| Change From Baseline at Week 24 (n=39) |
0.0
(0.28)
|
| Change From Baseline at Week 36 (n=34) |
0.0
(0.35)
|
| Change From Baseline at Week 48 (n=22) |
-0.1
(0.35)
|
| Change From Baseline at Week 60 (n=17) |
-0.1
(0.43)
|
| Change From Baseline at Week 72 (n=10) |
-0.1
(0.57)
|
| Change From Baseline at Week 84 (n=7) |
-0.1
(0.38)
|
| Change From Baseline at Follow Up (n=33) |
-0.1
(0.35)
|
| Title | Change From Baseline in CHAQ-DI (Arising) Score at Weeks 12, 24, 36, 48, 60, 72, 84 and End of Follow up |
|---|---|
| Description | The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Arising component was measured on 0-3 scale (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do). |
| Time Frame | Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety population. Here, 'n' signifies the number of participants with available data for specified category. |
| Arm/Group Title | Tocilizumab |
|---|---|
| Arm/Group Description | Participants received tocilizumab 8 mg/kg via IV infusion, once every 4 weeks for up to 104 weeks or until tocilizumab became commercially available, whichever occurred first. |
| Measure Participants | 41 |
| Baseline (n=41) |
0.0
(0.22)
|
| Change From Baseline at Week 12 (n=40) |
0.0
(0.23)
|
| Change From Baseline at Week 24 (n=40) |
0.0
(0.16)
|
| Change From Baseline at Week 36 (n=34) |
-0.0
(0.17)
|
| Change From Baseline at Week 48 (n=22) |
-0.0
(0.21)
|
| Change From Baseline at Week 60 (n=17) |
-0.1
(0.24)
|
| Change From Baseline at Week 72 (n=10) |
0.0
(0.0)
|
| Change From Baseline at Week 84 (n=7) |
0.0
(0.0)
|
| Change From Baseline at Follow Up (n=33) |
0.0
(0.17)
|
| Title | Change From Baseline in CHAQ-DI (Dressing and Grooming) Score at Weeks 12, 24, 36, 48, 60, 72, 84 and End of Follow up |
|---|---|
| Description | The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Dressing and Grooming component was measured on 0-3 scale (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do). |
| Time Frame | Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety population. Here, 'n' signifies the number of participants with available data for specified category. |
| Arm/Group Title | Tocilizumab |
|---|---|
| Arm/Group Description | Participants received tocilizumab 8 mg/kg via IV infusion, once every 4 weeks for up to 104 weeks or until tocilizumab became commercially available, whichever occurred first. |
| Measure Participants | 41 |
| Baseline (n=41) |
0.1
(0.42)
|
| Change From Baseline at Week 12 (n=40) |
0.0
(0.16)
|
| Change From Baseline at Week 24 (n=40) |
0.1
(0.22)
|
| Change From Baseline at Week 36 (n=34) |
0.1
(0.24)
|
| Change From Baseline at Week 48 (n=22) |
0.0
(0.31)
|
| Change From Baseline at Week 60 (n=17) |
0.0
(0.35)
|
| Change From Baseline at Week 72 (n=10) |
-0.2
(0.63)
|
| Change From Baseline at Week 84 (n=7) |
-0.3
(0.76)
|
| Change From Baseline at Follow Up (n=33) |
-0.1
(0.50)
|
| Title | Change From Baseline in CHAQ-DI (Eating) Score at Weeks 12, 24, 36, 48, 60, 72, 84 and End of Follow up |
|---|---|
| Description | The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Eating component was measured on 0-3 scale (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do). |
| Time Frame | Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety population. Here, 'n' signifies the number of participants with available data for specified category. |
| Arm/Group Title | Tocilizumab |
|---|---|
| Arm/Group Description | Participants received tocilizumab 8 mg/kg via IV infusion, once every 4 weeks for up to 104 weeks or until tocilizumab became commercially available, whichever occurred first. |
| Measure Participants | 41 |
| Baseline (n=41) |
0.1
(0.33)
|
| Change From Baseline at Week 12 (n=40) |
0.0
(0.23)
|
| Change From Baseline at Week 24 (n=40) |
0.0
(0.23)
|
| Change From Baseline at Week 36 (n=34) |
0.0
(0.25)
|
| Change From Baseline at Week 48 (n=22) |
-0.1
(0.29)
|
| Change From Baseline at Week 60 (n=17) |
0.1
(0.24)
|
| Change From Baseline at Week 72 (n=10) |
0.0
(0.0)
|
| Change From Baseline at Week 84 (n=7) |
-0.1
(0.38)
|
| Change From Baseline at Follow Up (n=33) |
-0.0
(0.30)
|
| Title | Change From Baseline in CHAQ-DI (Grip) Score at Weeks 12, 24, 36, 48, 60, 72, 84 and End of Follow up |
|---|---|
| Description | The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Grip component was measured on 0-3 scale (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do). |
| Time Frame | Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety population. Here, 'n' signifies the number of participants with available data for specified category. |
| Arm/Group Title | Tocilizumab |
|---|---|
| Arm/Group Description | Participants received tocilizumab 8 mg/kg via IV infusion, once every 4 weeks for up to 104 weeks or until tocilizumab became commercially available, whichever occurred first. |
| Measure Participants | 41 |
| Baseline (n=41) |
0.2
(0.40)
|
| Change From Baseline at Week 12 (n=40) |
-0.1
(0.22)
|
| Change From Baseline at Week 24 (n=40) |
-0.0
(0.16)
|
| Change From Baseline at Week 36 (n=34) |
-0.1
(0.29)
|
| Change From Baseline at Week 48 (n=22) |
-0.1
(0.29)
|
| Change From Baseline at Week 60 (n=17) |
0.1
(0.43)
|
| Change From Baseline at Week 72 (n=10) |
0.0
(0.47)
|
| Change From Baseline at Week 84 (n=7) |
-0.1
(0.38)
|
| Change From Baseline at Follow Up (n=33) |
-0.1
(0.29)
|
| Title | Change From Baseline in CHAQ-DI (Hygiene) Score at Weeks 12, 24, 36, 48, 60, 72, 84 and End of Follow up |
|---|---|
| Description | The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Hygiene component was measured on 0-3 scale (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do). |
| Time Frame | Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety population. Here, 'n' signifies the number of participants with available data for specified category. |
| Arm/Group Title | Tocilizumab |
|---|---|
| Arm/Group Description | Participants received tocilizumab 8 mg/kg via IV infusion, once every 4 weeks for up to 104 weeks or until tocilizumab became commercially available, whichever occurred first. |
| Measure Participants | 41 |
| Baseline (n=41) |
0.2
(0.44)
|
| Change From Baseline at Week 12 (n=40) |
-0.0
(0.16)
|
| Change From Baseline at Week 24 (n=40) |
0.0
(0.16)
|
| Change From Baseline at Week 36 (n=34) |
-0.1
(0.24)
|
| Change From Baseline at Week 48 (n=22) |
-0.1
(0.35)
|
| Change From Baseline at Week 60 (n=17) |
-0.1
(0.43)
|
| Change From Baseline at Week 72 (n=10) |
-0.1
(0.32)
|
| Change From Baseline at Week 84 (n=7) |
-0.4
(0.79)
|
| Change From Baseline at Follow Up (n=33) |
-0.2
(46)
|
| Title | Change From Baseline in CHAQ-DI (Reach) Score at Weeks 12, 24, 36, 48, 60, 72, 84 and End of Follow up |
|---|---|
| Description | The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Reach component was measured on 0-3 scale (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do). |
| Time Frame | Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety population. Here, 'n' signifies the number of participants with available data for specified category. |
| Arm/Group Title | Tocilizumab |
|---|---|
| Arm/Group Description | Participants received tocilizumab 8 mg/kg via IV infusion, once every 4 weeks for up to 104 weeks or until tocilizumab became commercially available, whichever occurred first. |
| Measure Participants | 41 |
| Baseline (n=41) |
0.2
(0.42)
|
| Change From Baseline at Week 12 (n=40) |
-0.0
(0.28)
|
| Change From Baseline at Week 24 (n=40) |
-0.1
(0.22)
|
| Change From Baseline at Week 36 (n=34) |
-0.0
(0.30)
|
| Change From Baseline at Week 48 (n=22) |
-0.1
(0.29)
|
| Change From Baseline at Week 60 (n=17) |
0.1
(0.43)
|
| Change From Baseline at Week 72 (n=10) |
0.0
(0.0)
|
| Change From Baseline at Week 84 (n=7) |
0.0
(0.0)
|
| Change From Baseline at Follow Up (n=33) |
-0.1
(0.38)
|
| Title | Change From Baseline in CHAQ-DI (Walking) Score at Weeks 12, 24, 36, 48, 60, 72, 84 and End of Follow up |
|---|---|
| Description | The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Walking component was measured on 0-3 scale (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do). |
| Time Frame | Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety population. Here, 'n' signifies the number of participants with available data for specified category. |
| Arm/Group Title | Tocilizumab |
|---|---|
| Arm/Group Description | Participants received tocilizumab 8 mg/kg via IV infusion, once every 4 weeks for up to 104 weeks or until tocilizumab became commercially available, whichever occurred first. |
| Measure Participants | 41 |
| Baseline (n=41) |
0.0
(0.16)
|
| Change From Baseline at Week 12 (n=40) |
0.0
(0.0)
|
| Change From Baseline at Week 24 (n=40) |
0.1
(0.22)
|
| Change From Baseline at Week 36 (n=34) |
0.0
(0.0)
|
| Change From Baseline at Week 48 (n=22) |
0.0
(0.0)
|
| Change From Baseline at Week 60 (n=17) |
0.1
(0.24)
|
| Change From Baseline at Week 72 (n=10) |
0.0
(0.0)
|
| Change From Baseline at Week 84 (n=7) |
0.0
(0.0)
|
| Change From Baseline at Follow Up (n=33) |
0.0
(0.0)
|
| Title | Absolute C-Reactive Protein Levels |
|---|---|
| Description | |
| Time Frame | Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, End of follow up (up to 101 weeks) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety population. Here, 'n' signifies the number of participants with available data for specified category. |
| Arm/Group Title | Tocilizumab |
|---|---|
| Arm/Group Description | Participants received tocilizumab 8 mg/kg via IV infusion, once every 4 weeks for up to 104 weeks or until tocilizumab became commercially available, whichever occurred first. |
| Measure Participants | 41 |
| Baseline (n=40) |
0.9468
(4.11395)
|
| Week 4 (n=39) |
0.9755
(1.71814)
|
| Week 8 (n=41) |
1.8995
(6.17464)
|
| Week 12 (n=41) |
1.7157
(3.07714)
|
| Week 16 (n=41) |
2.4115
(8.71986)
|
| Week 20 (n=39) |
0.9706
(2.67299)
|
| Week 24 (n=41) |
1.4893
(3.24038)
|
| Week 28 (n=40) |
2.2320
(5.51994)
|
| Week 32 (n=39) |
2.1713
(7.09086)
|
| Week 36 (n=35) |
1.6507
(4.81621)
|
| Week 40 (n=31) |
1.2562
(2.49440)
|
| Week 44 (n=26) |
1.1710
(1.96013)
|
| Week 48 (n=22) |
1.2382
(1.98754)
|
| Week 52 (n=22) |
1.2019
(1.71587)
|
| Week 56 (n=18) |
3.9651
(12.83795)
|
| Week 60 (n=17) |
2.6449
(8.93648)
|
| Week 64 (n=15) |
0.6341
(1.40213)
|
| Week 68 (n=11) |
0.5210
(1.49015)
|
| Week 72 (n=10) |
1.5263
(1.97617)
|
| Week 76 (n=8) |
2.0304
(2.49171)
|
| Week 80 (n=7) |
1.4975
(2.39680)
|
| Week 84 (n=7) |
11.4459
(25.92600)
|
| Week 88 (n=3) |
0.0704
(0.06935)
|
| Follow up (n=32) |
2.3169
(3.24139)
|
Adverse Events
| Time Frame | Baseline to 12 weeks after last actual study medication (up to 101 weeks) | |
|---|---|---|
| Adverse Event Reporting Description | Analysis was performed on safety population. | |
| Arm/Group Title | Tocilizumab | |
| Arm/Group Description | Participants received tocilizumab 8 mg/kg via IV infusion, once every 4 weeks for up to 104 weeks or until tocilizumab became commercially available whichever, occurred first. | |
All Cause Mortality |
||
| Tocilizumab | ||
| Affected / at Risk (%) | # Events | |
| Total | / (NaN) | |
Serious Adverse Events |
||
| Tocilizumab | ||
| Affected / at Risk (%) | # Events | |
| Total | 3/41 (7.3%) | |
| Injury, poisoning and procedural complications | ||
| Multiple injuries | 1/41 (2.4%) | |
| Investigations | ||
| Neutrophil count decreased | 1/41 (2.4%) | |
| Renal and urinary disorders | ||
| Proteinuria | 1/41 (2.4%) | |
Other (Not Including Serious) Adverse Events |
||
| Tocilizumab | ||
| Affected / at Risk (%) | # Events | |
| Total | 15/41 (36.6%) | |
| Blood and lymphatic system disorders | ||
| Neutropenia | 3/41 (7.3%) | |
| Infections and infestations | ||
| Pharyngitis | 6/41 (14.6%) | |
| Upper respiratory tract infection | 5/41 (12.2%) | |
| Bronchitis | 4/41 (9.8%) | |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.
Results Point of Contact
| Name/Title | Medical Communications |
|---|---|
| Organization | Hoffmann-LaRoche or Genentech, Inc |
| Phone | 800 821-8590 |
| genentech@druginfo.com |
- ML27783